Product
Fluzone HD
6 clinical trials
4 indications
Indication
COVID-19Indication
InfluenzaIndication
Respiratory Syncytial VirusIndication
HumanClinical trial
A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-06-10
Clinical trial
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of AgeStatus: Terminated, Estimated PCD: 2019-04-26
Clinical trial
Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years OldStatus: Completed, Estimated PCD: 2022-11-03
Clinical trial
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older AdultsStatus: Completed, Estimated PCD: 2018-03-14
Clinical trial
Non-inferiority Study of Adjuvanted vs. High Dose Flu Vaccine in Residents of Long Term CareStatus: Completed, Estimated PCD: 2023-01-31